Conditions: Acute Gouty Arthritis Flares
Keywords: gouty arthritis
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 136
Healthy volunteers: no

Brief summary:
This was an 18-month, multi-center, open-label, clinical extension study. Patients completing earlier second extension studies (CACZ885H2356E2 and CACZ885H2357E2) continued to be treated in this combined extension 3 study for any new gouty arthritis flare on demand with one subcutaneous (s.c.) injection of canakinumab 150 mg.

Detailed description:

Arms:
arm 1: canakinumab 150 mg s.c.

Interventions: intervention 1: ACZ885 intervention 2: Triamcinolone acetonide 40 mg
Intervention descriptions: intervention 1: canakinumab 150 mg s.c., given on demand upon new flares intervention 2: Participants received 40 mg intramuscular (IM)

Protocol document: